Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
Psychiatry Investigation
;
: 417-420, 2013.
Article
in English
| WPRIM
| ID: wpr-126137
ABSTRACT
Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Psychomotor Agitation
/
Schizophrenia
/
Serotonin
/
Fluvoxamine
/
Receptors, sigma
/
Akathisia, Drug-Induced
/
Neurodegenerative Diseases
/
Dyskinesias
/
Endoplasmic Reticulum
/
Hyperkinesis
Limits:
Humans
Language:
English
Journal:
Psychiatry Investigation
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS